Evotec and Vifor Pharma form joint venture for early development in nephrology
Hamburg, Germany; St. Gallen, Switzerland, November 6, 2019
Evotec SE and Vifor Pharma today announced the launch of a 50:50 joint venture focused on the discovery and development of novel nephrology therapeutics. Vifor Pharma will be benefiting from access to an external R&D capability for the development of its own nephrology pipeline, while Evotec will gain access to a commercial partner through outlicensing all nephrology assets developed through the joint venture to the Vifor Pharma Group.
Just – Evotec Biologics & Biocon Biologics sign licensing deal for a biosimilar asset
Hamburg, Germany, Seattle, USA, and Bengaluru, India, October 10, 2019
Evotec SE and Biocon Limited today announced that Biocon Biologics, a wholly owned subsidiary of Biocon Ltd, and Just – Evotec Biologics, wholly owned by Evotec, have entered into a strategic licensing agreement for an early-stage, pre-clinical biosimilar asset.
Evotec and Celmatix enter into strategic collaboration
Hamburg, Germany, and New York, USA, October 9, 2019
Evotec SE and Celmatix Inc., a precision medicine company with a proprietary multi-omics platform, today announced a partnership to develop pre-clinical programmes in prevalent but underserved conditions affecting women’s reproductive health, including polycystic ovary syndrome (“PCOS”), endometriosis, and infertility.
Evotec SE reports first half-year 2019 results and corporate updates
Hamburg, Germany, August 14, 2019
Evotec SE today reported financial results and corporate updates for the first half of 2019. Group revenues up 16% to € 207.1 m (H1 2018: € 178.9 m). Adjusted Group EBITDA up 51% to € 58.2 m (H1 2018: € 38.6 m). Unpartnered R&D expenses of € 18.7 m (H1 2018: € 10.0 m). Strong liquidity position of € 341.8 m (31 December 2018: € 149.4 m) following issue of € 250 m promissory note (Schuldschein) and final repayment of € 140 m acquisition bridge facility.
Evotec expands its iPSC discovery platform
Hamburg, Germany, July 15, 2019
Evotec SE today announced that the Company has acquired assets from the stem cell specialist Ncardia AG to advance Evotec’s iPSC platform, one of the leading iPSC-based discovery platforms in the industry.
Evotec and venture capital consortium form "Breakpoint Therapeutics GmbH"
Hamburg, Germany, July 8, 2019
Evotec SE today announced the formation of Breakpoint Therapeutics GmbH, a spin-off company focusing on the development of Evotec’s DNA damage response (“DDR”) portfolio, comprising discovery-stage assets and drug targets that promise broad therapeutic application in a variety of cancers. Breakpoint Therapeutics’ mission is to develop first and best-in-class oncology drugs that interfere with DNA repair and replication stress pathways to facilitate the cure of therapy-resistant cancers.
Evotec completes acquisition of Just Biotherapeutics
Hamburg, Germany, July 3, 2019
Evotec SE today announced that the strategic transaction to acquire Just Biotherapeutics (“Just.Bio”), signed on 20 May 2019, has been completed. The acquisition accelerates Evotec’s long-term strategy to be the industry partner of choice for external end-to-end innovation, strengthening Evotec’s multimodality approach to R&D. Evotec acquired Just.Bio to integrate their cutting-edge machine-learning technologies and agile, flexible methods for the design, development, and manufacturing of biologics into Evotec’s drug discovery offerings.
Evotec SE places first Schuldschein (Promissory note) worth € 250 m
Hamburg, Germany, June 26, 2019
Evotec SE announced today that the Company successfully issued a Schuldschein (promissory note) of € 250 m on the capital market. The Schuldschein was placed with a fixed and variable interest rate of on average below 1.5 percent over 3, 5, 7, and 10 years maturity. Following high demand from debt investors, which led to a significant oversubscription of the order book and attractive credit spreads, the initial target volume of € 100 m could be successfully increased to € 250 m.
Evotec, Sensyne Health, the University of Oxford, OSI, and OUI create new bridge partnership “LAB10x” in digital health
Hamburg, Germany and Oxford, UK, June 24, 2019
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced that it has entered into a new strategic partnership with the British clinical AI technology company Sensyne Health plc (LSE:SENS) (“Sensyne”), the University of Oxford, Oxford University Innovation Ltd (“OUI”, the university's research commercialisation company), and Oxford Sciences Innovation (“OSI”, the world's largest IP investment company dedicated to a single university) to fund a new BRIDGE called LAB10x.
New LAB150 project identified
Toronto, Canada, June 11, 2019
MaRS Innovation has announced the launch of a fifth project to be developed under the BRIDGE LAB150, a partnership between Evotec SE and MaRS Innovation. The aim of the project is to develop a novel rapid-acting antidepressant with the potential to provide patient relief much faster than conventional treatments.
Evotec receives $ 23.8 m grant to join the global fight against tuberculosis
Hamburg, Germany, June 10, 2019
Evotec SE today announced that the company has entered into a five-year partnership with the Bill & Melinda Gates Foundation to discover new treatment regimens that better address tuberculosis (“TB”), a severe global health burden and one of the leading causes of death due to infectious diseases worldwide. The current standard treatment regimen for TB consists of a minimum of 6 months of treatment with 4 drugs administered under direct observation, but treatment is much longer when TB is drug resistant.
Evotec and Celgene further expand iPSC collaboration including new cell type
Hamburg, Germany, June 5, 2019
Evotec SE announced today that its strategic alliance with Celgene Corporation (“Celgene”) has been expanded to include a new cell type triggering a payment of $ 9.0 m to Evotec. Evotec and Celgene initiated the collaboration in December 2016 to identify disease-modifying treatments for a broad range of neurodegenerative diseases.
Evotec publishes DDup 8: Evotec’s unique iPSC-based drug discovery platform
Hamburg, Germany, May 29, 2019
The 8th edition of DDup is dedicated to our highly innovative iPSC platform, which we started developing more than six years ago with the goal to industrialise iPSC-based drug screening in terms of throughput, reproducibility and robustness to reach highest industrial standards. Today, it represents one of the largest and most sophisticated iPSC platforms in the industry.
Evotec jump-starts biologics with acquisition of Just Biotherapeutics
Hamburg, Germany, May 20, 2019
Evotec SE announced today the signing of a definitive agreement under which Evotec will acquire Just Biotherapeutics, Inc. (“Just.Bio”), for up to $ 90 m including potential performance-based earn-out components expected within the next three years.
Evotec to attend upcoming investor conferences
Hamburg, Germany, May 15, 2019
Evotec SE announced today that its management will be presenting at and attending the following upcoming conferences:
Berenberg Conference USA 2019, Tarrytown, NY, USA
2019 RBC Capital Markets Global Healthcare Conference, New York, NY, USA
dbAccess Berlin Conference 2019, Berlin, Germany
Jefferies 2019 Healthcare Conference, New York, NY, USA
Evotec SE to report first quarter 2019 results on 14 May 2019
Hamburg, Germany, May 7, 2019
Evotec SE will report its financial results for the first quarter of 2019 on Tuesday, 14 May 2019. The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. Furthermore, the Management Board will present an outlook for fiscal year 2019. The conference call will be held in English.
Evotec completes repayment of € 140 m acquisition loan
Hamburg, Germany, April 18, 2019
Evotec SE today announced that it has completed the repayment of the € 140 m debt bridge facility Evotec drew down in context of the acquisition of Aptuit in 2017. Effective August 2017, Evotec acquired Aptuit, a partner research organisation for integrated outsourced drug discovery and development, for € 253.2 m in cash. This acquisition was financed through existing cash reserves and a new € 140 m senior debt bridge facility.
Evotec and Indivumed announce strategic drug discovery collaboration on precision medicine for colorectal cancer
Hamburg, Germany, April 11, 2019
Evotec SE and Indivumed GmbH announced today that they have entered into a research collaboration to discover and develop first-in-class therapeutics for the treatment of colorectal cancer (“CRC”). The collaboration, which runs for an initial term of two years, will combine Evotec’s proprietary bioinformatics analysis platform “PanHunter” as well as its small molecule and antibody discovery platforms with the CRC cohort of Indivumed’s true multi-omics cancer database “IndivuType”. The goal of this precision medicine collaboration is to deliver highly effective and durable treatments with clear strategies for CRC patient stratification.
Evotec AG completes conversion into Evotec SE
Hamburg, Germany, April 1, 2019
Evotec SE announced today that it has completed its conversion into a company under European law (Societas Europaea, “SE”) with its registration in the commercial register of the District Court of Hamburg. It will operate under the registered name Evotec SE with the commercial register number HRB 156381 effective immediately and its headquarters will remain in Hamburg. The new legal form has no impact on the Company’s day-to-day operations.
Evotec and The Mark Foundation for Cancer Research announce strategic collaboration in immuno-oncology
Hamburg, Germany, March 26, 2019
Evotec AG and The Mark Foundation for Cancer Research today announced that they have entered into a research collaboration to discover and develop first-in-class therapeutics in oncology. The collaboration, for an initial period of two years, is based on Evotec’s new proprietary drug discovery platform TargetAlloMod, which is focused on disrupting cell signalling via a novel mechanism of action. This approach is expected to deliver highly potent and more durable treatments for both clinically validated and novel immuno-oncology targets.
Evotec AG to report fiscal year 2018 results on 28 March 2019
Hamburg, Germany, March 21, 2019
Evotec AG will report its financial results for 2018 on Thursday, 28 March 2019. The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. Furthermore, the Management Board will present an outlook for fiscal year 2019. The conference call will be held in English.
Evotec and GARDP announce new partnership to discover novel antibiotics
Hamburg, Germany, and Geneva, Switzerland, March 19, 2019
Evotec AG and The Global Antibiotic Research and Development Partnership (“GARDP”) are today announcing the formation of a new strategic public-private partnership to tackle the growing threat of antimicrobial resistance (“AMR”). By joining forces, Evotec and GARDP will leverage their capabilities and networks to address drug-resistant bacterial infections. This includes bringing together GARDP’s clinical expertise and sustainable access commitment with Evotec’s leading drug discovery platform, expertise in medicinal chemistry and pharmacology, as well as its world-leading collection of bacterial pathogens.
Evotec to attend upcoming investor conferences
Hamburg, Germany, March 7, 2019
Evotec AG announced today that its management will be presenting at and attending the following upcoming conferences: BioCapital Europe, Bankhaus Lampe Deutschlandkonferenz, H.C. Wainwright Global Life Sciences Conference, Kempen & Co Life Sciences Conference.
Evotec receives milestone payment for start of second Phase II trial in its multi-target alliance with Bayer
Hamburg, Germany, February 28, 2019
Evotec AG announced today that another promising small molecule from its multi-target alliance with Bayer has advanced into Phase II clinical development for the treatment of persistent chronic cough. As a result of the trial initiation, Evotec received a payment of € 3 m. In October 2012, Evotec and Bayer began their multi-target discovery alliance with the shared goal to discover three clinical candidates with a focus in the field of endometriosis. The successful and productive long-term alliance ended in 2018, generating six first-in-class pre-clinical candidates three of which have progressed into Phase I clinical trials.
Two new LAB150 projects identified to create novel therapeutics for Cystic Fibrosis and Respiratory Syncytial Virus
Toronto, Canada, February 27, 2019
MaRS Innovation announced today the concurrent launch of two new LAB150 projects. These projects build on breakthroughs in disease-focused scientific research by prominent teams at The Hospital for Sick Children (SickKids) and the University of Toronto, both of which are Members of MaRS Innovation. The projects aim to develop novel therapeutics for the treatment of cystic fibrosis and of respiratory syncytial virus, respectively.
Evotec and Helmholtz Centre joining platforms and forces for novel antibiotics
Hamburg and Braunschweig, Germany, February 20, 2019
Evotec AG and the Helmholtz Centre for Infection Research (“HZI”) announced today a collaboration with the goal to address a major global health threat by developing novel antibiotics that overcome drug-resistant bacterial pathogens. Research activities will initially be focused on the optimisation of cystobactamids, a family of natural antibacterial products with innovative chemical scaffolds that are active against the most dangerous Gram-negative pathogens on the WHO priority list.
Evotec and Galapagos enter into collaboration in the field of fibrosis
Hamburg, Germany, and Mechelen, Belgium, February 7, 2019
Evotec AG and Galapagos NV today announced a global collaboration focused on a novel target for fibrosis and other indications. The collaboration concerns a small molecule programme, currently in pre-clinical development for the treatment of fibrotic diseases of the liver and other organs. The target has been identified and validated using Evotec’s proprietary platforms for fibrotic diseases and NASH. Evotec utilised its in-house assay development and drug screening capabilities to identify small molecule modulators against the target, which remains undisclosed.
Evotec receives milestone payment for start of Phase II clinical trial
Hamburg, Germany, January 24, 2019
Evotec AG announced today that it has earned a $ 2 m milestone payment from Second Genome, Inc., a leading microbiome science-based discovery & development company, for the initiation of a Phase II clinical study of SGM 1019, a first-in-class oral therapeutic for the treatment of nonalcoholic steatohepatitis (NASH). The Phase II trial of SGM-1019 has been initiated following the completion of two successful Phase I trials.
Cyprotex, an Evotec company, joins new European H2020 research project
Hamburg, Germany, January 16, 2019
Evotec AG announced today that Cyprotex, an Evotec Company, will participate in the new European collaborative project SCREENED which aims to develop new 3D in-vitro tests to overcome limitations of existing tests. SCREENED aims to develop three-dimensional (3D) cell-based in vitro tests to better characterise the effects of endocrine disruptors on thyroid gland function. This method will overcome the limitations of existing tests, being more sensitive at low doses of exposure to chemicals, and enabling the prediction of their toxicity on human health in a sex-specific manner.
Evotec reaches important scientific achievement within iPSC-based collaboration with Celgene
Hamburg, Germany, January 8, 2019
Evotec AG announced today that its strategic alliance with Celgene Corporation (“Celgene”) has reached another important scientific achievement, resulting in Celgene designating a programme and triggering a payment of $ 14.0 m to Evotec. The payment was received by year-end 2018. This scientific achievement was the advancement of a programme into the lead optimisation stage developed from Evotec’s compound library using its induced pluripotent stem cell (“iPSC”)-based screening platform. This programme can be further optimised and progressed towards IND-ready status.
Evotec invests in financing round of Exscientia
Hamburg, Germany, January 7, 2019
Evotec AG announced today an additional investment of approximately $ 6 m towards Exscientia’s latest funding round (Series B). Exscientia, the world-leading Artificial Intelligence (AI)-driven drug discovery company, has raised $ 26 m in a Series B financing round. Celgene Corporation and GT Healthcare Capital Partners joined as new investors and Evotec, previously the only large external investor, fully participated in this round.